Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 3,701–3,800 of 4,275
Brooks, H. W., Cusick, N. C., Wu, S., & Farr, J. N. (2026) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2026.102203
Endogenous DNA damage drives cellular senescence and promotes aging
Gregg, S. Q. (2011) · D-Scholarship@Pitt (University of Pittsburgh)
Malaquin, N., Carrier-Leclerc, A., Martinez, A., Dessureault, M., Ghadaouia, S., Coppé, J., Nadeau, S., Cardin, G. B., Campisi, J., & Rodier, F. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/413732
Self-citationOncogene-Induced Senescence Transcriptomes Signify Premalignant Colorectal Adenomas
Shboul, S. A., Awad, H., Abu-Humaidan, A. H. A., Ababneh, N. A., Khasawneh, A. I., & Saleh, T. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040221 · Cited by 2
“Senescent cells undergo broad gene expression alterations [11,12], which account for their ability to secrete a spectrum of soluble and insoluble factors into the microenvironment, collectively termed the senescence-associated secretory phenotype (SASP) [13].”
Výmolová, B., Pfeiferová, L., Smetana, T. K., Výmola, P., Ternerová, N., Zubal, M., Kolář, M., Šáchová, J., Gyönyörová, S., Balážiová, E., et al. (2026) · Brain Pathology · doi:10.1111/bpa.70129 · Cited by 1
“This lack of elevated IL-6 and CXCL12 secretion is intriguing, because both are well-established components of the so-called senescence-associated secretory profile (SASP) [9].”
Oh, J., Lee, J., Kim, E.-C., Kim, J.-R., Ha, H., Kim, T., Lee, K., & Jeong, D. (2025) · Cells · doi:10.3390/cells14241945 · Cited by 1
“To establish the connection between osteoblast differentiation and SASP production, we examined whether senescent osteoblast progenitors release SASP factors that impair osteogenesis [5,8].”
Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer
Hinterleitner, C., Barthet, V. J. A., Goldberg, H. V., Vogt, K. C., Perea, A. M., Hillger, L. R., Ruiz, S. B., McHugh, D., Ho, Y.-J., Perez, A. C., et al. (2026) · Science · doi:10.1126/science.aeg4791 · Cited by 2
Zhang, L., Luo, D., Zhang, J., Zhu, J., Gan, Y., Zhao, J., & Liu, M. (2023) · Research Square · doi:10.21203/rs.3.rs-2819399/v1
Sakuma, K., Endo, K., Ozeki, N., Koga, H., & Sekiya, I. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103497
Tissue factor links inflammation, thrombosis, and senescence in COVID-19Preprint
Nguyen, D., & Lee, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1855842/v1
Westin, E. R., Klingelhutz, A. J., Wallrath, L. L., McCray, P. B., Davidson, B. L., & Knudson, C. M. (2010) · doi:10.17077/etd.2xq96sz4
Martínez‐Zamudio, R. I., & Herbig, U. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_38
Targeting cellular senescence mitigates chemotherapy-induced bone loss in young and aged mice
Izquierdo, D. J., Blancarte-Hernández, E., Schurman, C. A., Schilling, B., Woloszyk, A., Aguilar, L., Salmon, A., & Glatt, V. (2026) · GeroScience · doi:10.1007/s11357-026-02485-4
White, S. V., Ma, Y. H. E., Plant, C. D., Harvey, A. R., & Plant, G. W. (2025) · Cells · doi:10.3390/cells14191488
Senescence in prostate cancer: is there sufficient evidence to move forward?
Carpenter, V. J., Autorino, R., & Gewirtz, D. A. (2021) · Minerva Urology and Nephrology · doi:10.23736/s2724-6051.21.04525-0
Philipot, D. (2012) · theses.fr (ABES) · doi:10.70675/9b4773fdz718bz4ff2za6ebz25081c8e24f5
Ohmori, K. (2025) · Biomolecules · doi:10.3390/biom15101431
“IL-6 and IL-8 are key mediators of cellular invasiveness, as neutralizing antibodies targeting these interleukins suppress invasion, and supplementation with recombinant IL-6 or IL-8 enhances the invasiveness of preneoplastic epithelial cells co-cultured with non-senescent fibroblasts [122].”
Mazeyrie, L. (2024) · theses.fr (ABES) · doi:10.70675/04dabd62z8f26z4393zac25z0070faaa4fb9
Research Advances on CXCL9-Mediated Inflammatory and Immune Regulation in Vascular Aging
唐, 安. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641242
Ochiiwa, H., Wakasa, T., Kataoka, Y., Ando, K., Oki, E., Maehara, Y., Iimori, M., & Kitao, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.03.636172 · Cited by 1
The Aged Microenvironment Influences Prostate Carcinogenesis
Bianchi-Frias, D. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada479324
Luo, X., Li, J., Qi, J., Lin, C., Wu, J., Jin, O., & Gu, J. (2026) · Rheumatology · doi:10.1093/rheumatology/keag429
Kim, E., Rebecca, V. W., Fedorenko, I. V., Messina, J. L., Mathew, R. A., Maria–Engler, S. S., Basanta, D., Smalley, K. S. M., & Anderson, A. R. A. (2023) · doi:10.1158/0008-5472.22398576.v1
Nie, P., Chen, J., & Zhang, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.21.581353
Progressive Senescence Programs Induce Intrinsic Vulnerability to Aging-related Breast CancerPreprint
Bai, H., Liu, X., Lin, M., Meng, Y., Li, N., Clarke, M. F., & Cai, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.08.539818
Ni, G., Ma, N., & Xu, J. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1801780
“…hallmark of senescence, resulting in a proinflammatory microenvironment comprising a plethora of soluble signaling factors, such as inflammaging-related factors, matrix metalloproteinases, and adhesion molecules, when it accumulates (Coppé et al., 2008; Kuilman et al., 2008; Kumari and Jat, 2021).”
Plasticité cellulaire et initiation tumorale dans le modèle du cancer du sein
Blander, H. D. (2020) · theses.fr (ABES) · doi:10.70675/c6b4eda8z19a5z4b3dzb7d9zacc5fd814b21
Development and Characterization of 3D Senescent Models Mimicking Skin Aging
Pentecouteau, L., Laperdrix, C., Rouxel, E., Folligné, A., Morvan, P., & Vallée, R. (2025) · Cosmetics · doi:10.3390/cosmetics12020071
“SASP is thought to contribute to the functional decline of the skin as a consequence of aging, through the establishment of a chronic inflammatory state and induction of senescence in normal cells [14,15].”
Perez, M. D., Zhu, F., Carlin, E., Greer, B. D., Schroeder, A. R., Lowman, K. E., Opsteen, S., Fram, T., Tidwell, C., Duverger, A. E., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag208
Usando Biologia de Sistemas para entender a Imunossenescência
Passos, F. M. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.95.2018.tde-20230725-114626
Schofield, A., Kamath, B., MacParland, S. A., Trauner, M., Trivedi, P., & Mann, J. P. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101778 · Cited by 1
蔡月丽 (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662307
Bonnefous, H. (2025) · theses.fr (ABES) · doi:10.70675/67742b4az1242z4d30z964ezd8bf9300d4ac · Cited by 1
(2014) · Elsevier eBooks · doi:10.1016/b978-1-907568-42-8.50016-2
Auswirkungen partikulärer Luftverschmutzung auf die menschliche Haut
Rolfes, K. M., Haarmann‐Stemmann, T., & Krutmann, J. (2025) · Die Dermatologie · doi:10.1007/s00105-025-05617-7
Typhoid toxin hijacks Wnt5a to potentiate TGFβ-mediated senescence and Salmonella infectionsPreprint
ElGhazaly, M., Collins, M. O., Ibler, A. E., & Humphreys, D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.05.510870
“Senescent cells release a signature pro-inflammatory secretome that establishes the senescence-associated secretory phenotype (SASP)(8-10).”
BackgroundDumont, S., Orbach, D. H., L’Herminé, A. C., & Robin, Y. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-24697-6_6
The Ets family transcription factor EHF suppresses senescence-associated inflammatory responsesPreprint
Fumoto, Y., Fujikawa, M., Katayama, Y., Mahandaran, T., Ishikawa, F., & Miyoshi, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.31.728776
“Moreover, SASP can alter the tumor microenvironment and promote the proliferation, migration, invasion, and metastasis of cancer cells, thereby contributing to the detrimental effects exerted by senescent cells 10,13,14 .”
The structural origin of irreversible transitions in biological networks
Kim, J., Jang, S., Lee, J., Hopper, C., & Cho, K. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2600800123
Hematopoietic Stem Cell Aging and Malignant Hemopathies
Goodhardt, M., Garrick, D., Dang, L., Salaroli, A., & Bron, D. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_71
Armartmuntree, N., Kaewlert, W., Aupatham, P., Buakaew, S., Sakonsinsiri, C., Lert-itthiporn, W., Pinlaor, S., & Thanan, R. (2026) · Oxidative Medicine and Cellular Longevity · doi:10.1155/omcl/3094707
“While senescence prevents the propagation of damaged cells, it is also associated with the secretion of proin fl ammatory factors collectively known as the SASP [35].”
Contribution of Extracellular Vesicles to Cancer Initiation through Cellular Senescence during Aging
Tominaga, N. (2018) · Cancer Studies · doi:10.31532/cancerstud.1.1.006
Blue period - features of senescence 30 years after beta-galactosidase
Kuehnemann, C., & Wiley, C. D. (2026) · Aging · doi:10.18632/aging.206380
“In 2008, a series of manuscripts identified a number of inflammatory cytokines and chemokines, growth factors, and matrix metalloproteinases as key molecules secreted by senescent cells [52 – 54].”
Zayan, T. A., & Khafagy, H. A. (2026) · World Advances in Renal Medicine · doi:10.25259/warm_15_2026
Ponte, F., Kim, H., Warren, A. D., Iyer, S. V., Li, H., Mannen, E. M., Gómez-Acevedo, H., Nookaew, I., Almeida, M., & Manolagas, S. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.15.452452
Perdichizzi, B., Cappiello, F., Feo, F. D., Pera, L. L., Pagliuca, A., Valenzisi, P., Rosina, M., Merlo, D., Franchitto, A., & Pichierri, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.20.745990
“Secretory responses are well documented downstream of DNA damage, oncogene-induced replication stress and senescence (20, 38, 39), but whether a perturbation below the threshold for checkpoint enforcement is sufficient to reprogram the secretome has not been addressed.”
Zhu, R., Wang, Q., Su, X., Yin, K., & Zhao, R. C. (2021) · Research Square · doi:10.21203/rs.3.rs-634834/v1
The Role of NAD+-Dependent Signal Mechanisms in Cancer Development and Treatment
Lu, T., Qin, Z., & Wu, J. (2025) · Springer eBooks · doi:10.1007/978-981-97-9877-3_33 · Cited by 1
Senescence-Associated Beta-Galactosidase Marker of Cellular Senescence
Dimri, M., & Dimri, G. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11446-1 · Cited by 1
An RNA Signature Links Oxidative Stress To Cellular Senescence
Mullani, N. (2019) · theses.fr (ABES) · doi:10.70675/1babf95cz77a0z4561za6cdz6bf733f9f455
Ikuno, Y., Watanabe, K., Kakeya, Y., Ikeno, S., Nakabo, T., Narumoto, A., Kande, Y., Hayashi, T., Minami, K., Nobuhiro, K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2204556/v1
Romagnani, C. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0219-8_2
Senescence in Oncogenesis: From Molecular Mechanisms to Therapeutic Opportunities
Muñoz-Galván, S., & Carnero, A. (2014) · Springer eBooks · doi:10.1007/978-94-017-9421-3_7
Dissecting the molecular mechanism and spatiotemporal dynamics controlling senescence entry
Sofiadis, K. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8409
Notch signalling mediates secondary senescencePreprint
Teo, Y. V., Rattanavirotkul, N., Salzano, A., Quintanilla, A., Tarrats, N., Kiourtis, C., Mueller, M., Green, A. R., Adams, P. D., Acosta, J. C., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/554741
Sharma, J., Mondal, S., Bisht, K. S., Biswas, A., Panneerselvam, L., Maiti, T. K., & Mathew, S. J. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08962-0
“Senescent cells secrete pro-in fl ammatory signals, broadly known as senescence-associated secretory phenotype (SASP) [28, 29].”
Data from The BH3 Mimetic ABT-737 Induces Cancer Cell Senescence
Song, J. H., Kandasamy, K., Zemskova, M., Lin, Y., & Kraft, A. S. (2023) · doi:10.1158/0008-5472.c.6501588
Küçükgüven, A., & Vargel, İ. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98804-9.00003-7
Sam, C., & Negrete‐Najar, J. P. (2019) · Springer eBooks · doi:10.1007/978-3-319-44870-1_64-1
Stress-driven strategic games in cancer
Özcan, S. C. (2026) · Biosystems · doi:10.1016/j.biosystems.2026.105929
Biomaterials regulate cellular senescence for the treatment of H. pylori-related gastric cancer
Gong, Y., Chen, Y., Zhang, T., Xu, Z., Wu, Y., Li, Z., Du, Y., & Gao, J. (2026) · TransMed · doi:10.1016/j.tmed.2026.100055
The role of Banf1 in mechanisms of cellular ageing and cancer prognosis
Plowman, J. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.247163
Xia, Q., Cheng, Y., Ma, L., Lu, Z., Lu, Q., zeng, N., wang, Z., & Luo, D. (2022) · Research Square · doi:10.21203/rs.3.rs-2237515/v1
Data from The BH3 Mimetic ABT-737 Induces Cancer Cell Senescence
Song, J. H., Kandasamy, K., Zemskova, M., Lin, Y., & Kraft, A. S. (2023) · doi:10.1158/0008-5472.c.6501588.v1
Cellular Senescence and Biliary Disorders
Sasaki, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-3500-5_4
Therapeutic targeting of the leukaemic fusion genes
Issa, H. (2019)
Ohtani, N. (2015) · Journal of The Society of Japanese Women Scientists · doi:10.5939/sjws.15002
Senescent Subtypes Transition ModelPreprint
Singh, G. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.10.544466
“Senescent cells accumulate over time and can have both beneficial and detrimental effects through the secretion of factors called as the senescence-associated secretory phenotype (SASP) [35] or senescence-messaging secretome [36].”
BackgroundCellular Aging and Metabolites in Aging
Kondoh, H., Mikawa, T., & Kameda, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_4
Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level
Singh, A., Misra, A., & Zaheer, S. (2026) · Aging and Cancer · doi:10.1002/aac2.70027
Impact of aging on cardiac mesenchymal stromal cells
Martini, H. (2019) · theses.fr (ABES) · doi:10.70675/bb7ddcb3z0b6az4c39za6eczc94e0563f0a3
Costa, J. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Waaijer, M. E. C., Tuttle, C. S. L., Westendorp, R. G. J., & Maier, A. B. (2018) · VU Research Portal
Proteomic analysis of human keratinocytes under UVA-induced stress
Valerio, H. P. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2021.tde-28042022-144138
The senescent mesothelial matrix accentuates colonization by ovarian cancer cellsPreprint
Thapa, B. V., Glimm, T., Saini, D. K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.02.543239
Chen, M., Pan, Y., Zhang, J., & Zeng, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s548070
Senescence Biomarkers Independently Predict Disease-Related Mortality in Chronic Kidney DiseasePreprint
McLarnon, T., Ghazinader, D., Watterson, S., Lennox, L., Duncan, J., McCarroll, F., & Singh, T. (2026) · Research Square · doi:10.21203/rs.3.rs-10539671/v1
Coronado, R. E. (2026) · GeroScience · doi:10.1007/s11357-026-02554-8
Osteoimmunology: interactions of the bone and immune system
Mo, Q., Jiang, Y., Han, X., Li, C., & Tang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1925819
Akt/Foxo pathway activation switches apoptosis to senescence in short telomere zebrafishPreprint
Maï, M. E., Marzullo, M., de Castro, I. P., & Ferreira, M. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.10.901603
Manjunath, G. K., Nashier, D., & Kumar, A. (2026) · Archives of Medical Research · doi:10.1016/j.arcmed.2026.103384 · Cited by 1
The Comparison Between the Two Paradigms
Libertini, G., Corbi, G., Conti, V., Shubernetskaya, O. S., & Ferrara, N. (2021) · Advances in studies of aging and health · doi:10.1007/978-3-030-73774-0_4
Cellular senescence and other aging mechanisms in bone and muscle
Kaur, J., & Farr, J. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820088-9.00008-1
Prevention and Treatment of the Troubles of the Elderly
Libertini, G., Corbi, G., Conti, V., Shubernetskaya, O. S., & Ferrara, N. (2021) · Advances in studies of aging and health · doi:10.1007/978-3-030-73774-0_8
Vascular aging and cardiovascular diseases
Zhao, Y., Wu, A., LiYong, L. I. A. O., Liu, M., XueTing, G. O. N. G., & Tian, X. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0344
Dynamics and Aging of Hematopoietic Stem Cells
van Os, R. P., & de Haan, G. (2014) · CRC Press eBooks · doi:10.1201/b16962-3
Dinislam, K., Shamsi, A., Syed, T., Anwar, S., & Shahwan, M. J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1830358 · Cited by 1
“Despite a halt in the telomere attrition process due to cell cycle arrest, the chronic inflammatory environment created by SASP can contribute to the slow progression of various age-related conditions (Coppé et al., 2008; Cuollo et al., 2020; Libby et al., 2009; Shakeri et al., 2018).”
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.